Skip to main content
Equibles
DMII logo

DMII · Drugs Made In America Acquisition II Corp. · Metrics

Track DMII — free

Use DMII with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research DMII.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$10.19 -0.01 (-0.05%)
Rebalance outlook locked
Going-concern doubt — flagged Aug 14, 2026

Substantial doubt about the company's ability to continue as a going concern.

“management has determined that these conditions raise substantial doubt about the Company's ability to continue as a going concern within one year after the date that the financial statements are issued. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.”
View the 10-Q filed Aug 14, 2026
Market Cap
$649.42M
Shares
63.70M
Volume · Oct 26 188.03K Avg daily vol (3M) 132.67K

DMII metrics

46 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$10.20
Market cap
$649.42M

Price action

20 metrics
Price change (1W)
+0.2%
Price change (30D)
+0.2%
Price change (3M)
+0.9%
Price change (6M)
+1.9%
Price change (YTD)
+3.0%
Price change (1Y)
—
Trailing year
Price change (5Y)
—
52-week high
—
52-week low
—
Change from 52-week high
—
Change from 52-week low
—
Annualized volatility
1.9%
Annualized volatility (3M)
—
Beta
0.0
RSI (14D)
62.8
Price vs SMA 50
+0.3%
Price vs SMA 200
+1.5%
Avg volume (3M)
132,667
Relative volume
1.4
Average dollar volume
$1.35M

Company

3 metrics
Sector
Financial Services
Industry
Shell Companies
Shares outstanding
63.70M

Valuation

12 metrics
P / E (TTM)
49.9
Trailing earnings · reciprocal yield 2.0%
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
—
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
2.0%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$635,242
Net income (TTM)
$13.02M
Trailing 12 months
Diluted EPS (TTM)
—
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$-1.30

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
-4.7%
Year over year · fewer shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
—
Return on assets
2.5%
Debt / equity
—
Current ratio
0.3
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
0.3
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
−$275,026
Latest balance sheet
Cash & equivalents
$174,974
Total assets
$514.10M
Total debt
$450,000

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$1.28M
Capital expenditures (TTM)
—
R&D (TTM)
—
SG&A (TTM)
—
Stock compensation (TTM)
—
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
85
13F filer change QoQ
+3
Institutional ownership
141.3%
Conviction holders (share of 13F filers)
7.1%
Crowding (high-turnover and private-fund holders)
58.3%
Private-fund adviser ownership
46.5%
Active holders' share change QoQ
+3.5%
Holder tenure
2.7
Price vs estimated holder cost
+1.4%

Ownership (registered funds)

1 metrics
Index-fund ownership
0.0%

Short interest

3 metrics
Short interest
0.2%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
42 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 2040475 CUSIP G2851K104 13F (30d) 3 filings 3 filers